Publication
Somatically mutated ABL1 is an actionable and essential NSCLC survival gene.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (10)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 10
- cancerLung Adenocarcinomacivic_curation1.00
- cancerLung Non-Small Cell Carcinomacivic_curation1.00
- drugDasatinibcivic_curation1.00
- drugImatinibcivic_curation1.00
- drugImatinib Mesylatecivic_curation1.00
- geneABL1civic_curation1.00
- geneABL2civic_curation1.00
- variantABL1 G340Lcivic_curation1.00
- variantABL1 R351Wcivic_curation1.00
- variantABL2 W469Ccivic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26758680
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| ABL2 W469C1 | ||||||||
| Dasatinib + ImatinibSubstitutes | Lung Adenocarcinoma | Predictive | D | Does Not Support Sensitivity Response | 3 | accepted | EID10077Four lung adenocarcinoma cell lines were studied with mutations in ABL1 or ABL2. Sensitivity to imatinib or dasatinib treatment was measured by reduction in colony formation in response to treatment. … (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC | civic |
| ABL2 Y399C1 | ||||||||
| Dasatinib + ImatinibSubstitutes | Lung Adenocarcinoma | Predictive | D | Does Not Support Sensitivity Response | 3 | rejected | EID10078Four lung adenocarcinoma cell lines were studied with mutations in ABL1 or ABL2. Sensitivity to imatinib or dasatinib treatment was measured by reduction in colony formation in response to treatment. … (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC | civic |
| ABL1 G340L1 | ||||||||
| Dasatinib + Imatinib MesylateSubstitutes | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 3 | accepted | EID4788In this in vitro study, the H2110 non-small cell lung cancer cell line (heterozygous for a G340L mutation) was shown to be susceptible to imatinib and dasatinib monotherapies. This line showed a signi… (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC | civic |
| ABL1 R351W2 | ||||||||
| Dasatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 4 | accepted | EID4787In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to dasatinib. This line showed a significant reduction in colony fo… (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC | civic |
| Imatinib | Lung Non-Small Cell CarcinomaCURATED_BROADER | Predictive | D | Supports Sensitivity Response | 5 | accepted | EID6376In this in vitro study, the H1915 non-small cell lung cancer cell line (homozygous for a R351W mutation) was shown to be susceptible to imatinib. This line showed a significant reduction in colony for… (full text at CIViC) PMID 26758680 · Testoni et al., 2016 · Open in CIViC | civic |